Is RXRX a Buy? What to Consider in 2026
Short answer
The bull case for Recursion Pharmaceuticals (RXRX) rests on An industrial-scale AI platform and proprietary data moat: Recursion's core argument is that drug discovery becomes a data and compute problem at scale. Revenue (Q1 2026) is ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. Whether RXRX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026) and comes mostly from partnerships rather than drug sales. Recursion went public in 2021 and has built its profile around scale and compute. It owns BioHive, an NVIDIA-built supercomputer (BioHive-2 is powered by dozens of NVIDIA DGX H100 systems and hundreds of H100 GPUs), and NVIDIA has been both a technology partner and an investor, which fueled the market's framing of Recursion as an AI-biotech bellwether. In 2024 Recursion agreed to merge with UK-based Exscientia in a roughly $700 million all-stock deal that closed and combined two AI drug-discovery leaders, bringing together partnerships with Roche-Genentech and Bayer (Recursion) and Sanofi and Merck KGaA (Exscientia). Since the merger the company has reworked and prioritized its pipeline, cut operating expenses, and emphasized extending its cash runway while advancing a handful of Phase 2 clinical programs.
What's the case for buying RXRX?
An industrial-scale AI platform and proprietary data moat
Recursion's core argument is that drug discovery becomes a data and compute problem at scale. It has run vast numbers of automated biological experiments to build one of the largest proprietary maps of cellular biology, the kind of dataset that is expensive and slow for others to reproduce. The bet is that this data advantage, fed into machine-learning models, can surface drug targets and candidates faster and at lower cost than conventional trial-and-error chemistry.
A deep big-pharma partnership book
Recursion has signed collaborations with major drug makers including Roche-Genentech, Bayer, Sanofi, and Merck KGaA. Management has pointed to more than $20 billion in potential future milestone payments across these deals, before any royalties on net sales. These partnerships validate the platform externally, fund operations with non-dilutive cash, and give Recursion multiple shots on goal without bearing all the clinical cost itself.
The NVIDIA tie and owned supercomputing
Recursion owns BioHive, an NVIDIA-built supercomputer that the company has described as among the most powerful AI systems wholly owned by any biopharma. NVIDIA has been a technology collaborator and investor, reinforcing the narrative that Recursion sits at the intersection of AI infrastructure and biology. Owning its compute lets Recursion train large biological models on its own data without renting capacity from cloud providers.
A broadened, post-merger pipeline
The Exscientia merger combined Recursion's biology-first platform with Exscientia's molecular design and added clinical assets and partnerships. The company now advances several wholly owned Phase 2 programs, including REC-4881 in familial adenomatous polyposis (granted FDA Fast Track and an EU orphan designation) and REC-994 in cerebral cavernous malformation. Pipeline breadth gives the platform several independent chances to produce a clinical win that would re-rate the whole thesis.
What are the risks to RXRX?
The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Recursion's Phase 2 candidates could fail in trials like most clinical-stage biotech assets do, and even partnered programs depend on decisions outside Recursion's control. Although the company guides to a cash runway into early 2028, continued losses mean it may need to raise capital again, and equity raises would dilute existing shareholders; the stock has also been volatile, trading well below prior highs.
How is RXRX valued? (as of 2026-06-27)
- Revenue (Q1 2026): ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates)
- Net loss (Q1 2026): ~$117.5 million (narrowed from the prior year on cost cuts)
- Cash and investments: ~$665 million (as of March 31, 2026)
- Guided 2026 operating cash burn: less than ~$390 million; stated runway into early 2028 without new financing
- Market capitalization: ~$1.9 billion (June 2026)
- Profitability and dividend: Not profitable; pays no dividend
Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. Q1 2026 showed narrower losses driven by sizable cuts to R&D and overhead, which extended the stated runway into early 2028, but revenue came in well below analyst expectations. For a story like this, valuation is ultimately a bet on future platform output and partnership milestones rather than on current financial performance.
How do you decide if RXRX is a buy?
Rather than asking whether RXRX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold RXRX indirectly through an index or sector ETF before adding more.
For the full picture, see the RXRX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RXRX against your real portfolio and see your actual exposure before deciding.
The bottom line on RXRX
The bottom line: Recursion Pharmaceuticals's story right now is An industrial-scale AI platform and proprietary data moat, with revenue (q1 2026) at ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). If you believe that narrative continues, the call is about sizing RXRX sensibly and checking overlap with what you own; if you doubt it (the risk: the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around RXRX with Walnut
Use Recursion Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is RXRX a good stock to buy right now?
+
The case for Recursion Pharmaceuticals right now is An industrial-scale AI platform and proprietary data moat, with revenue (q1 2026) at ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates). If you believe that thesis holds, RXRX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Recursion Pharmaceuticals do?
+
Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery.
What are the main risks of RXRX?
+
The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Recursion's Phase 2 candidates could fail in trials like most clinical-stage biotech assets do, and even partnered programs depend on decisions outside Recursion's control. Although the company guides to a cash runway into early 2028, continued losses mean it may need to raise capital again, and equity raises would dilute existing shareholders; the stock has also been volatile, trading well below prior highs.
Is RXRX a good stock to buy right now?
+
That depends entirely on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a scaled AI platform, deep pharma partnerships, and a cash runway into early 2028. The bear case is that Recursion has no approved drug, loses over $100 million a quarter, and could fail in trials or need dilutive financing. It is a speculative, high-volatility holding, not a stable one.
What does Recursion Pharmaceuticals do?
+
Recursion is a clinical-stage biotech that aims to industrialize drug discovery using artificial intelligence. It runs automated biology experiments at massive scale, captures the results as proprietary imaging data, and uses machine-learning models, plus Exscientia's molecular design tools, to identify and design drug candidates. It earns money mainly through partnerships with large pharma companies and is advancing its own pipeline of experimental medicines.
Is RXRX profitable?
+
No. Recursion is not profitable and remains deeply loss-making, reporting a net loss of roughly $117.5 million in the first quarter of 2026 against only about $6.5 million of revenue. Like most clinical-stage biotech companies, it spends heavily on research and trials years before any product could generate meaningful sales, so profitability is not expected in the near term.
Does RXRX pay a dividend?
+
No. Recursion does not pay a dividend and is not expected to. As an unprofitable, cash-burning clinical-stage company, it directs all available capital toward research, clinical trials, and its computing platform rather than returning cash to shareholders. Investors in a stock like this are betting on potential future share-price appreciation, not income.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell RXRX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.